Cargando…
Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease
Over the past few decades, a series of innovative medicines have been developed in order to optimize anticoagulation therapy for atrial fibrillation (AF). As a result, a number of nonvitamin K antagonist oral anticoagulants (NOAC) that directly target the enzymatic activity of factor II and factor X...
Autores principales: | Stoica, Mihai Ciprian, Gáll, Zsolt, Gliga, Mirela Liana, Căldăraru, Carmen Denise, Székely, Orsolya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147111/ https://www.ncbi.nlm.nih.gov/pubmed/33925501 http://dx.doi.org/10.3390/medicina57050422 |
Ejemplares similares
-
Prevalence of oral anticoagulation in atrial fibrillation
por: Bartholomay, Eduardo, et al.
Publicado: (2014) -
Satisfaction with oral anticoagulants in patients with atrial fibrillation
por: Suárez Fernández, Carmen, et al.
Publicado: (2018) -
Oral Anticoagulation in Patients with Chronic Kidney Disease and Non-Valvular Atrial Fibrillation: The FAERC Study
por: Montomoli, Marco, et al.
Publicado: (2022) -
Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Advanced Chronic Kidney Disease: CODE-AF Registry
por: Park, Hanjin, et al.
Publicado: (2023) -
Tailored Direct Oral Anticoagulation in Patients with Atrial Fibrillation: The Future of Oral Anticoagulation?
por: Samoš, Matej, et al.
Publicado: (2022)